Five Strategic Reasons to Include MRI Biomarkers in Your Next Parkinson’s Study
Parkinson’s Disease (PD) is the second most prevalent neurodegenerative disorder worldwide. Over 750 industry clinical trials have been initiated for...
At RSNA 2022, our team discussed the latest advances in imaging trials software, including state-of-the-art digital biomarkers algorithms.
Parkinson’s Disease (PD) is the second most prevalent neurodegenerative disorder worldwide. Over 750 industry clinical trials have been initiated for...
It is difficult to diagnose Parkinson’s disease, and the only way to confirm diagnosis is postmortem. The new imaging AI tools could be the answer.
Prof. Russ Hornbeck shares insights on Alzheimer's research and imaging technology through his experience in medical imaging, discussing the DIAN...